These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 35144542)
1. Contribution of classification based on ferroptosis-related genes to the heterogeneity of MAFLD. Dai X; Zhang R; Wang B BMC Gastroenterol; 2022 Feb; 22(1):55. PubMed ID: 35144542 [TBL] [Abstract][Full Text] [Related]
2. Use of a ferroptosis-related gene signature to construct diagnostic and prognostic models for assessing immune infiltration in metabolic dysfunction-associated fatty liver disease. Lian X; Tang X Front Cell Dev Biol; 2023; 11():1199846. PubMed ID: 37928903 [No Abstract] [Full Text] [Related]
3. Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link? Feng G; Byrne CD; Targher G; Wang F; Zheng MH Liver Int; 2022 Jul; 42(7):1496-1502. PubMed ID: 35007392 [TBL] [Abstract][Full Text] [Related]
4. Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis. Tong J; Lan XT; Zhang Z; Liu Y; Sun DY; Wang XJ; Ou-Yang SX; Zhuang CL; Shen FM; Wang P; Li DJ Acta Pharmacol Sin; 2023 May; 44(5):1014-1028. PubMed ID: 36323829 [TBL] [Abstract][Full Text] [Related]
5. Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation. Yang M; Xia L; Song J; Hu H; Zang N; Yang J; Zou Y; Wang L; Zheng X; He Q; Liu J; Liu F; Liang K; Sun L; Chen L Lipids Health Dis; 2023 Nov; 22(1):202. PubMed ID: 38001459 [TBL] [Abstract][Full Text] [Related]
6. Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis. Ke Y; Liu S; Zhang Z; Hu J Lipids Health Dis; 2021 May; 20(1):55. PubMed ID: 34034750 [TBL] [Abstract][Full Text] [Related]
7. The Gut Microbiome and Ferroptosis in MAFLD. Ji J; Wu L; Wei J; Wu J; Guo C J Clin Transl Hepatol; 2023 Feb; 11(1):174-187. PubMed ID: 36406312 [TBL] [Abstract][Full Text] [Related]
8. LncPRYP4-3 serves as a novel diagnostic biomarker for dissecting subtypes of metabolic associated fatty liver disease by targeting RPS4Y2. Yang H; Li Q; Zhang L; Zhu M; Niu J; Xue F; Yang L; Qu Q; Lao Y; Ding Z; Xiao C; Wang K Clin Exp Med; 2020 Nov; 20(4):587-600. PubMed ID: 32494880 [TBL] [Abstract][Full Text] [Related]
9. The gut microbiota metabolite glycochenodeoxycholate activates TFR-ACSL4-mediated ferroptosis to promote the development of environmental toxin-linked MAFLD. Liu S; Gao Z; He W; Wu Y; Liu J; Zhang S; Yan L; Mao S; Shi X; Fan W; Song S Free Radic Biol Med; 2022 Nov; 193(Pt 1):213-226. PubMed ID: 36265794 [TBL] [Abstract][Full Text] [Related]
10. Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models. Zhao QY; Ge LH; Zhang K; Chen HF; Zhan XX; Yang Y; Dang QL; Zheng Y; Zhou HB; Lyu JX; Fang HZ Zool Res; 2020 Sep; 41(5):539-551. PubMed ID: 32786176 [TBL] [Abstract][Full Text] [Related]
11. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. Huang SC; Su HJ; Kao JH; Tseng TC; Yang HC; Su TH; Chen PJ; Liu CJ Gut Liver; 2021 May; 15(3):451-458. PubMed ID: 33431715 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822 [TBL] [Abstract][Full Text] [Related]
13. Si-Wu-Tang alleviates metabolic dysfunction-associated fatty liver disease by inhibiting ACSL4-mediated arachidonic acid metabolism and ferroptosis in MCD diet-fed mice. Xue X; Wang L; Wu R; Li Y; Liu R; Ma Z; Jia K; Zhang Y; Li X Chin Med; 2024 Jun; 19(1):79. PubMed ID: 38844978 [TBL] [Abstract][Full Text] [Related]
14. Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study. Fukunaga S; Nakano D; Kawaguchi T; Eslam M; Ouchi A; Nagata T; Kuroki H; Kawata H; Abe H; Nouno R; Kawaguchi K; George J; Mitsuyama K; Torimura T Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34067258 [TBL] [Abstract][Full Text] [Related]
16. Association between the severity of metabolic dysfunction-associated fatty liver disease and the risk of colorectal neoplasm: a systematic review and meta-analysis. Zeng Y; Cao R; Tao Z; Gao Y Lipids Health Dis; 2022 Jun; 21(1):52. PubMed ID: 35668493 [TBL] [Abstract][Full Text] [Related]
17. MAFLD and risk of CKD. Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070 [TBL] [Abstract][Full Text] [Related]
18. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882 [TBL] [Abstract][Full Text] [Related]
20. The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C. Al-Omary A; Byth K; Weltman M; George J; Eslam M J Dig Dis; 2022 Jan; 23(1):33-43. PubMed ID: 34902220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]